Pfizer (PFE) reported positive findings from Cohort 3 of the pivotal BREAKWATER trial, a separate randomized cohort assessing BRAFTOVI (encorafenib) combined with cetuximab (ERBITUX®) and FOLFIRI in patients with previously untreated BRAF V600E–mutated metastatic colorectal cancer.
At the time of analysis, the BRAFTOVI combination with FOLFIRI and cetuximab showed a clear improvement in tumor response compared with standard treatment, with response rates of 64.4% versus 39.2%.
“These data further strengthen the potential utility of BRAFOTVI for patients with BRAF V600E-mutant metastatic colorectal cancer. The significant improvement in response rates reflects the meaningful clinical benefit of this targeted combination therapy regimen for patients,” said Jeff Legos, Chief Oncology Officer, Pfizer (PFE).
